Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

menu

Wilmot Research

Wilmot Cancer Institute / Research / Funding Opportunities / Wilmot Early-Stage Clinical Investigator Program

Wilmot Early-Stage Clinical Investigator Program

Application Deadline: August 28, 2024

The Wilmot Early-Stage Clinical Investigator (ESCI) Program aims to prepare early-stage physician-scientists at Wilmot to pursue a career involving leadership of investigator-initiated therapeutic clinical trials where the primary endpoint is a cancer outcome. Emphasis is on building institutional expertise and capacity to translate Wilmot science into therapeutic clinical trials. Successful ESCI awardees will go on to receive training and career development awards, lead clinical trials as principal investigators or co-investigators, or serve as members and leaders of local clinical trial committees and groups, such as the Protocol Review and Monitoring Committee, the Data and Safety Monitoring Committee, Disease Working Groups, and Translational Research Groups. ESCI participants are supported for one year and must dedicate at least 20% effort to the program. The program does not support clinical effort.

Apply

For more details and application instructions, download the RFA. 

Contact

For questions regarding the application process or program administration, contact Nicole O’Dell, Ph.D., program administrator.